Department of Microbiology and Infectious Diseases, University of Sherbrooke, Quebec.
Can J Infect Dis Med Microbiol. 2009 Winter;20(4):e163-8. doi: 10.1155/2009/971624.
An increased incidence of urinary tract infections (UTIs) caused by ciprofloxacin-gentamicin-resistant Escherichia coli (CiGREC) has been observed in a tertiary care centre in Sherbrooke, Quebec. The risk factors for such infections remained unclear.
To determine risk factors for, and outcomes of, CiGREC UTIs, a case control study was conducted. Between 2000 and 2007, 93 cases and 186 controls were identified using laboratory records of patients with greater than 10(7) colony-forming units/L of E coli in a urinary specimen. Cases had E coli with minimum inhibitory concentration to ciprofloxacin of 4 mg/L or greater and minimum inhibitory concentration to gentamicin of 8 mg/L or greater (CiGREC), and controls had E coli with any other susceptibility pattern to ciprofloxacin and gentamicin. Clinical and laboratory data were collected. Adjusted odds ratios (AOR) and their 95% CIs were calculated by logistic regression.
The prevalence of CiGREC increased sixfold during the study period. Risk factors associated with CiGREC UTI were advanced age, male sex, urological abnormality, domicile outside Sherbrooke, living in a nursing home (AOR 11.73; 95% CI 3.70 to 37.15), use of fluoroquinolones (AOR 15.24; 95% CI 5.42 to 42.83) or aminoglycosides (AOR 6.59; 95% CI 1.22 to 35.61) within the previous month, and use of fluoroquinolones during the preceding one to 12 months (AOR 2.45; 95% CI 1.06 to 5.62). Compared with controls, cases were more likely not to receive an active antibiotic as empirical or definitive treatment, and were more likely to relapse.
In the future, it may become necessary to avoid selecting as empirical therapy of urinary tract infection an antibiotic to which the patient has been recently exposed.
在魁北克舍布鲁克的一家三级保健中心,观察到由环丙沙星-庆大霉素耐药大肠杆菌(CiGREC)引起的尿路感染(UTI)发病率增加。导致这些感染的危险因素仍不清楚。
为了确定 CiGREC UTI 的危险因素和结果,进行了病例对照研究。在 2000 年至 2007 年间,使用患者尿液标本中大肠杆菌菌落形成单位大于 10(7)的实验室记录,确定了 93 例病例和 186 例对照。病例组的大肠杆菌对环丙沙星的最小抑菌浓度为 4 mg/L 或更高,对庆大霉素的最小抑菌浓度为 8 mg/L 或更高(CiGREC),对照组的大肠杆菌对环丙沙星和庆大霉素的任何其他药敏模式均有反应。收集临床和实验室数据。通过逻辑回归计算调整后的优势比(AOR)及其 95%置信区间。
在研究期间,CiGREC 的患病率增加了六倍。与 CiGREC UTI 相关的危险因素包括年龄较大、男性、泌尿系统异常、居住地不在舍布鲁克、居住在养老院(AOR 11.73;95%CI 3.70 至 37.15)、在过去一个月内使用氟喹诺酮类药物(AOR 15.24;95%CI 5.42 至 42.83)或氨基糖苷类药物(AOR 6.59;95%CI 1.22 至 35.61),以及在过去 1 至 12 个月内使用氟喹诺酮类药物(AOR 2.45;95%CI 1.06 至 5.62)。与对照组相比,病例组更有可能不接受经验性或明确治疗的活性抗生素,更有可能复发。
将来,可能需要避免将患者最近接触过的抗生素作为尿路感染的经验性治疗选择。